Category: Biotech
-
SmallCaps Daily Sits Down with Milton Werner, President and CEO of Inhibikase Therapeutics
CEO and President, Milton Werner shares Inhibikase’s vision, achievements, and future endeavors in neurological diseases while highlighting the significant progress of the company’s lead candidate, risvodetinib, in its Phase 2 trial for Parkinson’s.
-
Travere’s Recent Breakthrough Drug Sends Its Stock Soaring: What Investors Need To Know Now!
Travere Therapeutics’ completion of a successful pre-NDA meeting with the U.S. FDA for Filspari in IgA nephropathy has sent its stock skyrocketing by more than 30% in a single trading session.
-
Pond Technologies: Value Through Vertical Integration Creates Catalysts For Investors
With increasing industrial activity resulting in a significant impact on the environment, CO2 abatement has become an urgent need for many industries. Every major industry that produces carbon dioxide through its operationsis required to have a green strategy involving carbon dioxide abatement and a low carbon emissions strategy. With the importance of low-carbon technologies growing…
-
Quipt Home Medical Corp: The Deeply Undervalued Home Medical Company Helping Create a Safer Post Pandemic World
Quipt Home Medical is a leader in providing clinical respiratory equipment including BiPAP and CPAP machines, oxygen concentrators, sleep apnea and PAP treatment equipment, ventilators, nebulizers and more.
-
Massive Breakthrough for Young Biotech Company Longeveron, Shown in Promising Phase 2b Trial Results
Young and dynamic biotech company Longeveron (Nasdaq:LGVN) announced topline results of their Phase 2b study of Lomecel-B for aging frailty, most notably showing a statistically significant dose-response relationship from baseline. Partially funded by a Small Business Innovation Research (SBIR) grant from the National Institute of Aging, this trial evaluated the safety and efficacy of a…
-
Longeveron (LGVN): The Highest Growth Potential Company Presenting at the AAIC
It is estimated that 44 million people globally are suffering from Alzheimer’s disease with 5.5 million of them in the US. Alzheimer’s is the sixth leading cause of death in America increasing by 89% since 2000 and is expected to reach a projected market size of $5.6 billion by 2027. Every year the most cutting-edge…
-
Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides’ SARS-CoV-2 Therapeutics Program
Shelton, Connecticut — July 8, 2020 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that excellent safety and tolerability of the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases was observed in an…
-
Pressure Bio: The $3.5 Million Order For Hand Sanitizers Could Really Increase The Momentum Of This Stock
Pressure Bio (OTCPK:PBIO) is one of the most promising microcaps that has been covered by us over the past few months. The company has been in the news for having a three-way merger which was announced on April 30, 2020. With a new name for the conglomerate and a new CEO in the form of…
-
U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus Drug Development Efforts
SHELTON, CONNECTICUT — April 6, 2020 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a leader in the development of highly effective antiviral drugs based on a novel, patented, nanomedicines platform, reports that U.S. Senator Richard Blumenthal visited the Company’s facility in Shelton, Connecticut, on Tuesday, March 31, 2020. The Honorable Senator Blumenthal visited…
-
Nemaura Medical to Launch their non-invasive continuous glucose monitor in the US market under the Wellness Category
Given some recent news, we think investors should take the time to research Nemaura Medical Inc. (NASDAQ: NMRD)